TY - JOUR
T1 - Differential effects of vascular endothelial growth factor A isoforms in a mouse brain metastasis model of human melanoma
AU - Küsters, Benno
AU - De Waal, Robert M.W.
AU - Wesseling, Pieter
AU - Verrijp, Kiek
AU - Maass, Cathy
AU - Heerschap, Arend
AU - Barentsz, Jelle O.
AU - Sweep, Fred
AU - Ruiter, Dirk J.
AU - Leenders, William P.J.
PY - 2003/9/1
Y1 - 2003/9/1
N2 - We reported previously that vascular endothelial growth factor isoform A (VEGF-A) expression by Mel57 human melanoma cells led to tumor progression in a murine brain metastasis model in an angiogenesis-independent fashion by dilation of co-opted, pre-existing vessels and concomitant enhanced blood supply (B. Kusters et al., Cancer Res., 62: 341-345, 2002). Here, we compare the activities of the 121, 165, and 189 VEGF-A isoforms in this model by transfecting Mel57 cells with the respective cDNAs and by injecting the resulting stably transfected cell lines in the internal carotid arteries of nude mice (n = 10 for each isoform). Although the three isoforms had similar potency to induce endothelial cell proliferation, VEGF121 expression did not result in sprouting angiogenesis but rather led to extensive vasodilation and increased permeability of preexisting, predominantly peritumoral vessels. Sometimes, proliferating endothelial cells accumulated in vessel lumina, giving these a microvascular, glomeruloid, proliferation-like appearance. Expression of VEGF165 or VEGF189 was associated with induction of an intratumoral neovascular bed. In VEGF 165-expressing tumors, daughter endothelial cells were distributed among newly formed vessels that were extensively dilated. This also occurred in VEGF189 tumors, but there, vasodilation was less pronounced. Using contrast-enhanced magnetic resonance imaging, the different vascular phenotypes were visualized on characteristic radiological images. VEGF165 expression was the most unfavorable of the three. Mice carrying VEGF 165 tumors became moribund earlier than those carrying VEGF 121-expressing tumors (16 ± 4 days versus 22 ± 3 days). Our data demonstrate that VEGF-A isoforms differ in angiogenic properties that can be visualized by contrast-enhanced magnetic resonance imaging.
AB - We reported previously that vascular endothelial growth factor isoform A (VEGF-A) expression by Mel57 human melanoma cells led to tumor progression in a murine brain metastasis model in an angiogenesis-independent fashion by dilation of co-opted, pre-existing vessels and concomitant enhanced blood supply (B. Kusters et al., Cancer Res., 62: 341-345, 2002). Here, we compare the activities of the 121, 165, and 189 VEGF-A isoforms in this model by transfecting Mel57 cells with the respective cDNAs and by injecting the resulting stably transfected cell lines in the internal carotid arteries of nude mice (n = 10 for each isoform). Although the three isoforms had similar potency to induce endothelial cell proliferation, VEGF121 expression did not result in sprouting angiogenesis but rather led to extensive vasodilation and increased permeability of preexisting, predominantly peritumoral vessels. Sometimes, proliferating endothelial cells accumulated in vessel lumina, giving these a microvascular, glomeruloid, proliferation-like appearance. Expression of VEGF165 or VEGF189 was associated with induction of an intratumoral neovascular bed. In VEGF 165-expressing tumors, daughter endothelial cells were distributed among newly formed vessels that were extensively dilated. This also occurred in VEGF189 tumors, but there, vasodilation was less pronounced. Using contrast-enhanced magnetic resonance imaging, the different vascular phenotypes were visualized on characteristic radiological images. VEGF165 expression was the most unfavorable of the three. Mice carrying VEGF 165 tumors became moribund earlier than those carrying VEGF 121-expressing tumors (16 ± 4 days versus 22 ± 3 days). Our data demonstrate that VEGF-A isoforms differ in angiogenic properties that can be visualized by contrast-enhanced magnetic resonance imaging.
UR - http://www.scopus.com/inward/record.url?scp=0141816826&partnerID=8YFLogxK
M3 - Article
C2 - 14500375
AN - SCOPUS:0141816826
SN - 0008-5472
VL - 63
SP - 5408
EP - 5413
JO - Cancer Research
JF - Cancer Research
IS - 17
ER -